BioVendor Group Unveils Latest Innovations in Immunodiagnostics and Molecular Diagnostics
|
By LabMedica International staff writers Posted on 08 Feb 2024 |
|
BioVendor Group (Brno, Czech Republic) is participating in Medlab Middle East 2024 where it is unveiling the latest innovations in immunodiagnostics and molecular diagnostics. Visitors to the BioVendor booth at the show can explore its portfolio and meet experts from BioVendor LM, BioVendor MDx, TestLine, DiaSource, and ViennaLab to discuss how its advancements can benefit their work in the field of laboratory medicine.
BioVendor Group CLIA solution brings a fully automated walk-away platform, which significantly increases the efficiency of the laboratory workflow. It redefines the standards of fluency of diagnostic laboratories and provides reliable results. The KleeYa analyzer is also part of the booth and is being demonstrated to visitors by an application specialist. The KleeYa analyzer is an open platform system that handles tests from various providers and can combine a wide variety of assay designs. KleeYa provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment.
At the BioVendor booth, TestLine is presenting its latest innovations in laboratory diagnostics that are shaping the future of diagnostics. Visitors can explore the versatility of its Microblot-Array technology and its impact on the development of laboratory diagnostics worldwide. Microblot–Array is a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing. Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS.
DiaSource ImmunoAssays is also sharing the same booth as BioVendor Group where it is presenting its latest diagnostic devices, recent innovations, and equipment in the fields of immunodiagnostics and molecular diagnostics. On display are the company’s RIA instruments, IMMUNOBLOT instruments, ELISA instruments, and CLIA instruments. Experts from BioVendor MDx are presenting its expanded fastGEN portfolio with user-friendly kits for the analysis of various genes. The latest addition is the fastGEN TP53 Cancer kit which is intended for the detection of mutations in exons 2-11 as well as in the two non-canonical exons between exons 9 and 10. Visitors to the booth can also learn more about the all-in-one solution fastGEN including bioinformatic analysis software GENOVESA.
Latest Medlab 2024 News
- Anbio Biotechnology Presents Point-Of-Care IVD Solutions
- 77 Elektronika Showcases Latest Developments in Urinalysis
- Sansure Presents Future of Pathogen Identification and Disease Diagnosis
- Spinreact Presents Latest Developments in IVD
- Alifax Demonstrates Automated Solutions to Improve Performance in Laboratory Settings
- YHLO Unveils New iBC 900 Automated Chemistry Analyzer
- Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics
- Dymind Introduces New High-End Hematology Analyzer with Innovative Functions
- DIRUI Exhibits Latest Lab Automation Technologies and Devices
- Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer
- Boule Presents Next Generation Hematology and Clinical Chemistry Systems
- bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution
- BioPerfectus Highlights Diagnostic Solutions for HPV & Cervical Cancer Screening, STIs and Vector-Borne Diseases
- Mindray Showcases Range of Advanced Total IVD Solutions
- Medlab Middle East 2024 Provides a Peek into the Laboratory of the Future
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more
Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Molecular Diagnostics
view channel
Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
Neonatal diabetes is a rare form of diabetes that presents in the first six months of life and is driven by genetic changes, yet many affected families still lack definitive diagnoses. Genetic studies... Read more
Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide are now widely used for weight management, yet individual responses vary considerably, with some patients experiencing... Read more
Hematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Immunology
view channel
Combined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Pathology
view channel
AI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more_image.png "Image: Through neoadjuvant therapy combining chemotherapy with immune checkpoint inhibitors (ICI) for 46 LAGC patients and single-cell transcriptome sequencing, researchers found that tumor cells in the treatment-sensitive group specifically upregulated MHC-II (tumor-specific major histocompatibility complex class II, tsMHC-II) molecules (photo courtesy of Science China Press)")
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read more
Technology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read more
Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more
